Humacyte, Inc. Common Stock
Veridion Score
Composite trend over time
Why is HUMA moving today?
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for HUMA.
HUMA insider activity
Humacyte, Inc. Common Stock
2 insiders bought in the last 90 days
Net selling: -$7.5M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | 2026-05-19 | Sebelius Kathleen | Insider | buy | $0.88 | 56,818 | 148,025 | $50K | SEC Form 4 |
| 2026-05-20 | 2026-05-18 | Parikh Shamik J | Insider | sell | $0.90 | 45,887 | 272,713 | $41K | SEC Form 4 |
| 2026-05-20 | 2026-05-18 | Sander Dale A. | Insider | sell | $0.90 | 45,887 | 267,213 | $41K | SEC Form 4 |
| 2026-05-20 | 2026-05-18 | Constantino Michael T. | Insider | buy | $0.89 | 11,000 | 43,950 | $10K | SEC Form 4 |
| 2025-08-20 | 2025-08-20 | Dougan Brady W | Insider | sell | $1.58 | 591,685 | Not reported | $935K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 5 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moHUMA contract awards, year to date.
Public federal awards linked to this ticker.
HUMA lobbying filings, year to date.
Registered lobbying filings matched to Humacyte, Inc. Common Stock.